Nygaard M, Hovgaard D, Schjødt I M, Andersen N S, Vindeløv L, Sengeløv H
Hematological department, National University Hospital Rigshospitalet, Copenhagen, Denmark.
J Clin Pharm Ther. 2015 Jun;40(3):358-61. doi: 10.1111/jcpt.12266. Epub 2015 Mar 31.
The target level and route of administration of cyclosporine A (CsA) differ between transplantation centres. It is unclear whether oral CsA is sufficient to maintain target level of CsA.
We retrospectively analysed data from 48 adult patients, who underwent myeloablative hematopoietic stem cell transplantation. Twenty-one patients (44%) tolerated CsA orally throughout the transplantation period without increased incidence of acute graft versus host disease(aGVHD). Low concentration of CsA in week 2 was associated with increased incidence of aGVHD.
Oral administration of CsA is safe, less time-consuming and economically advantageous. Close monitoring of CsA concentration is important.
不同移植中心环孢素A（CsA）的目标水平和给药途径存在差异。口服CsA是否足以维持CsA的目标水平尚不清楚。
我们回顾性分析了48例接受清髓性造血干细胞移植的成年患者的数据。21例患者（44%）在整个移植期间口服CsA耐受，急性移植物抗宿主病（aGVHD）发生率未增加。第2周CsA浓度低与aGVHD发生率增加相关。
口服CsA安全、省时且经济实惠。密切监测CsA浓度很重要。
